The ****** alzheimer’s drugs market reached a value of US$ 6.34 Billion in 2020. Looking forward, the market is expected to grow at a CAGR of 6.50% during the forecast period (2021-2026), according to the latest report by IMARC Group.
Alzheimer’s disease (AD) is a chronic or persistent disorder that attacks the brain cells, affecting memory, thinking and behavior. Alzheimer’s drugs refer to medications that help lessen symptoms, such as memory loss and confusion, for a limited time. These drugs also influence the functions of neurotransmitters, the chemicals involved in carrying messages between nerve cells in the brain.
The ****** Alzheimer’s drugs market is primarily driven by the increasing number of people diagnosed with Alzheimer’s disease. Besides this, the increasing prevalence of chronic diseases, such as diabetes, obesity, heart diseases and high blood pressure (BP), that increase the risk of Alzheimer’s are contributing to the market. This is further supported by unhealthy dietary patterns, sedentary lifestyles and smoking, which are known to increase the chances of developing Alzheimer’s disease. Moreover, several pharmaceutical companies are developing drugs that prevent the disease and provide long-lasting improvements in cognitive functions. The development of these drugs is anticipated to propel market growth in the coming years.
Get a PDF Sample for more detailed market insights: https://www.imarcgroup.com/alzeimers-drugs-market/requestsample
Note: We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
****** Alzheimer’s Drugs Market 2021-2026 Analysis and Segmentation:
The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.
Abbvie Inc., AstraZeneca PLC, Biogen Inc., Daiichi Sankyo Company Limited, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Eli Lilly and Company, H. Lundbeck A/S, F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, Ono Pharmaceutical Co. Ltd., Pfizer Inc and Teva Pharmaceutical Industries Limited.
For more information about this report visit: https://www.imarcgroup.com/alzeimers-drugs-market
The report has segmented the market on the basis of Type, Thickness, Production Process, Application and Region.
Market Breakup by Drug Class:
Market Breakup by Distribution Channel:
Market Breakup by Region:
Middle East and Africa
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
30 N Gould St
Sheridan, WY 82801
Email: [email protected]
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800
Follow us on twitter: @imarcglobal